脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)多克隆抗體(生物素標(biāo)記)
Biotin-Linked Polyclonal Antibody to Phospholipase A2 Group VII (LpPLA2)
PLA2G7; PAF-AH; PAFAH; Lp-PLA2; LDL-PLA2; Platelet Activating Factor Acetylhydrolase,Plasma; Phospholipase A2,Group VII; LDL-associated phospholipase A2; Phospholipase A2, Lipoprotein Associated
- 編號(hào)ULAA867Hu71
 - 物種Homo sapiens (Human,人) 相同的名稱,不同的物種。
 - 來源抗體標(biāo)記
 - Ig類型 IgG
 - 純化方式抗原特異性親和純化
 - 標(biāo)記物生物素
 - 原抗體 -
 - 緩沖液成份磷酸鹽緩沖液(pH7.4,含有0.02% NaN3和50%甘油)
 - 性狀液體
 - 濃度500μg/mL
 - 且適物種-
 - 應(yīng)用WB; IHC; ICC.
如果抗體需用于流式細(xì)胞術(shù),請參見流式抗體。 - 下載 英文說明書 中文說明書
 - 規(guī)格 20μl100μl 200μl 1ml 10ml
 - 價(jià)格 ¥ 311 ¥ 727 ¥ 1038 ¥ 2595 ¥ 10380
 - 欲了解實(shí)際交易價(jià)格和更多情況,請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
 
特異性
該抗體是針對LpPLA2的兔多克隆抗體。在免疫組織化學(xué)染色和免疫印跡實(shí)驗(yàn)中能識(shí)別LpPLA2。
用法
            
                        免疫印跡:0.2-2μg/mL;1:250-2500
                        
 免疫組織化學(xué):5-20μg/mL;1:25-100
                        
 免疫細(xì)胞化學(xué):5-20μg/mL;1:25-100
                        
 最佳稀釋倍數(shù)最終由用戶決定。
                        
        
儲(chǔ)存
經(jīng)常使用則4°C保存。-20°C保存不超過兩年。避免反復(fù)凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定,具體方法如下:在37°C孵育48小時(shí),沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲(chǔ),損失率低于5%。
贈(zèng)品
增值服務(wù)
            Protein-A/G純化柱
                    細(xì)胞和組織染色液
                    抗體陽性對照品
                    組織/切片定制服務(wù)
                    磷酸化抗體定制服務(wù)
                    免疫印跡(WB)實(shí)驗(yàn)服務(wù)
                    免疫組織化學(xué)(IHC)實(shí)驗(yàn)服務(wù)
                    免疫細(xì)胞化學(xué)(ICC)實(shí)驗(yàn)服務(wù)
                    流式細(xì)胞術(shù)(FCM)實(shí)驗(yàn)服務(wù)
                    免疫沉淀(IP)實(shí)驗(yàn)服務(wù)
                    免疫熒光(IF)實(shí)驗(yàn)服務(wù)
                    緩沖液
                    DAB顯色試劑盒
                    SABC試劑盒
                    實(shí)時(shí)熒光定量PCR實(shí)驗(yàn)服務(wù)
                            
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種:Homo sapiens (Human,人) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) | 
| URPA867Hu02 | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. | 
| URPA867Hu03 | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. | 
| URPA867Hu04 | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. | 
| UAPA867Hu01 | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)活性蛋白 | Cell?culture;?Activity?Assays. | 
| URPA867Hu01 | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. | 
| UPAA867Hu01 | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)多克隆抗體 | WB | 
| ULAA867Hu81 | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. | 
| ULAA867Hu71 | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. | 
| UMAA867Hu21 | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)單克隆抗體 | WB; IHC; ICC; IP. | 
| UMAA867Hu22 | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)單克隆抗體 | WB; IHC; ICC; IP. | 
| USEA867Hu | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. | 
| USCA867Hu | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)檢測試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. | 
| ULMA867Hu | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. | 
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) | 
| Science & Sports | The effects of different intensity walking programs on serum blood lipids, high-sensitive C-reactive protein, and lipoprotein-associated phospholipase A2 in premenopausal women [ScienceDirect: S0765159710000262] | 
| Metabolic Syndrome and Related Disorders | Association of Serum Lipoprotein-Associated Phospholipase A2 Level with Nonalcoholic Fatty Liver Disease [Wiley: source] | 
| 34 | Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study [PubMed: 22240497] | 
| PLoS ONE | Effects of Lipid-Lowering Drugs on Irisin in Human Subjects In Vivo and in Human Skeletal Muscle Cells Ex Vivo [PubMed: PMC3759413] | 
| China Pharmacy | Influence of Tongfengtai Granules on Inflammatory Factor in Acute Gouty Arthritis Model Rats [Source] | 
| Atherosclerosis | Everolimus therapy is associated with reduced lipoprotein-associated phospholipase A2 (Lp-Pla2) activity and oxidative stress in heart transplant recipients. [Pubmed: 23958269] | 
| Journal of Diabetes Research | Lipoprotein-Associated Phospholipase A2 Mass Level Is Increased in Elderly Subjects with Type 2 Diabetes Mellitus [Hindawi: 278063] | 
| Health | The Role of Asymmetric Dimethylarginine and Lipoprotein Associated Phospholipase A2 in Children and Adolescents with Dyslipidemia [Scirp:Source] | 
| Biology Bulletin | In vitro lipid-lowering and fibrinolytic effects of regulatory leucine-containing glyprolines in human blood [Springer:Source] | 
| Gynecol Endocrinol. | Lipoprotein-associated phospholipase A2 and AGEs are associated with cardiovascular risk factors in women with history of gestational diabetes mellitus. [Pubmed:24397392] | 
| Journal of Diabetes Research | Lipoprotein-Associated Phospholipase A 2 Mass Level Is Increased in Elderly Subjects with Type 2 Diabetes Mellitus [Pubmed:24818163] | 
| Metabolism. | Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes [Pubmed:25034387] | 
| J Am Heart Assoc | Effect of Extended‐Release Niacin on High‐Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin‐Treated Patients [PubMed: 26374297] | 
| Czecho-Slovak Dermatology / Cesko-Slovenska Dermatologie | V [Ebscohost] | 
| Endocrinol Metab (Seoul). | Effect of Pitavastatin Treatment on ApoB-48 and Lp-PLA2?in Patients with Metabolic Syndrome: Substudy of PROspective Comparative Clinical Study Evaluating the Efficacy and Safety of PITavastatin in Patients with Metabolic Syndrome [pmc:PMC4803547] | 
| Clin Pharmacol Ther.? | Effect of dipyridamole on myocardial reperfusion injury: A double‐blind randomized controlled trial in patients undergoing elective coronary artery bypass surgery [Pubmed:25773594] | 
| Lipids in Health and Disease | Effect of intensive insulin treatment on plasma levels of lipoprotein-associated phospholipase A 2 and secretory phospholipase A 2 in patients with newly … [articles:10.1186] | 
| Acta Endocrinologica | SERUM LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN MALES WITH METABOLIC SYNDROME AND OBSTRUCTIVE SLEEP APNEA. [jrnl:1841098] | 
| Biomarker for diagnosis of moyamoya disease [:] | |
| JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION | Circulating fatty-acid binding-protein 4 levels predict CV events in patients after coronary interventions [Pubmed: 32859455] | 
| chinese neurosurgical journal | Can admission lipoprotein-associated phospholipase A2 predict the symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage? [] | 

                    
                    
                            